Intermediate Uveitis
What is Intermediate Uveitis?
Intermediate uveitis is inflammation centered primarily on the vitreous body and the pars plana region of the eye. It can affect people of all ages but is most common in children, adolescents, and young adults. The inflammation can occur alone or with other systemic conditions and may cause long-term vision issues if untreated.
Intermediate uveitis is a type of eye inflammation primarily involving the vitreous gel and the pars plana, a part of the eye behind the iris near the retina. When inflammation causes the appearance of white, fluffy accumulations called 'snowbanking,' the condition is sometimes called pars planitis.
This condition accounts for about 10–20% of all uveitis cases. It occurs mostly in people aged 10 to 40, with a slight female predominance. Children can also be affected and require close monitoring due to risks to eye development.
The vitreous is a clear gel filling most of the eye’s interior. Inflammation causes cells and debris to float in this gel, leading to visual disturbances. The pars plana is a narrow area between the retina and ciliary body that nourishes the eye and is often involved in the condition.
The disease can have a variable course, with some patients experiencing mild symptoms that resolve and others having recurrent inflammation needing long-term treatment. Prompt treatment improves chances of good vision, while complications can include cataracts, glaucoma, and retinal problems.
Causes and Risk Factors
Intermediate uveitis can arise from autoimmune diseases, infections, or unknown causes. Identifying underlying factors helps in choosing appropriate therapies.
Autoimmune disorders such as multiple sclerosis, sarcoidosis, and juvenile idiopathic arthritis can cause the immune system to attack eye tissues, triggering inflammation.
Infections like tuberculosis, Lyme disease, and syphilis may cause or mimic intermediate uveitis. Testing for these infections is important before starting immune-suppressing treatments.
Many cases have no identifiable cause despite thorough evaluation. These idiopathic cases still require monitoring and treatment to prevent vision loss.
There may be a genetic predisposition in some individuals. Environmental exposures may also contribute, but evidence is limited.
Signs and Symptoms
Symptoms often develop gradually and may be subtle, making early diagnosis challenging. Recognizing symptoms helps prompt timely treatment.
Patients commonly see small, moving spots or lines caused by inflammatory debris floating in the vitreous. Floaters are more visible against bright backgrounds and may fluctuate with disease activity.
Blurred or hazy vision occurs due to vitreous inflammation or swelling in the central retina. Vision changes may be intermittent or persistent.
Discomfort is often mild, described as a dull ache or pressure. Severe pain and redness are uncommon and may indicate other eye problems.
Inflammation can make eyes more sensitive to bright light, causing glare or discomfort indoors and outdoors.
- Mild redness or tearing, less common than in anterior uveitis
- Night vision difficulties or increased glare around lights, less frequent
- Children may show signs like eye rubbing, squinting, or school performance decline
Diagnosis
A comprehensive eye exam with specialized imaging and lab tests is essential to confirm intermediate uveitis and rule out other causes.
Doctors use slit-lamp and indirect ophthalmoscopy to detect inflammatory cells, vitreous haze, and characteristic snowbanking on the retina’s edge.
Optical coherence tomography (OCT) detects retinal swelling, especially cystoid macular edema. Fundus photography tracks progression, and fluorescein angiography assesses blood vessel leakage.
Blood tests screen for infections and autoimmune diseases. Chest imaging or neurological evaluations may be needed for systemic associations.
Regular visits assess inflammation control, side effects of treatment, and early signs of complications for timely intervention.
Treatment Options
Treatment aims to control inflammation, relieve symptoms, prevent vision loss, and manage underlying causes when found.
Topical steroids treat mild inflammation but have limited effect on the deeper parts of the eye affected in intermediate uveitis.
Oral steroids are used for more severe or bilateral cases, with gradual dose reduction to minimize side effects. Immunosuppressive drugs may be prescribed to reduce steroid use.
Steroid injections around or inside the eye can deliver medicine directly to the affected area. These are done in-office and may last several months.
Vitrectomy surgery removes inflammatory debris and treats complications like retinal detachment. It's reserved for refractory or complicated cases.
Systemic diseases linked to intermediate uveitis require coordinated care with other specialists and disease-specific treatments.
New biologic drugs targeting immune pathways are being studied and may offer options for resistant cases.
Children need careful management to protect visual development and reduce side effects from systemic treatments.
Managing Intermediate Uveitis Long Term
Effective long-term care includes regular eye exams, medication adherence, lifestyle measures, and patient education to maintain vision and quality of life.
Periodic visits allow monitoring of inflammation, treatment side effects, and early detection of complications.
Taking medications exactly as prescribed is critical for disease control and preventing relapses.
- Eat a balanced diet rich in fruits, vegetables, and omega-3 fatty acids
- Engage in regular physical activity and stress management
- Avoid smoking and excessive alcohol consumption
Sunglasses with UV protection can reduce light sensitivity. Safety glasses protect against injury during activities that risk eye trauma.
Patients should watch for new vision changes, eye pain, increased floaters, or flashes of light and report them promptly to their eye doctor.
Understanding the nature of the disease and treatment importance helps patients participate actively in their care and follow-up.
Collaboration among ophthalmologists, rheumatologists, and other specialists ensures comprehensive management, especially when systemic diseases are involved.
Adjustments such as magnifiers, screen font size increases, or low vision services can help maintain independence during flare-ups.
Participation in clinical trials may provide access to new treatments for severe or resistant disease.
Frequently Asked Questions
With timely and appropriate treatment, most patients maintain good vision. However, untreated or recurrent inflammation can lead to complications such as cataracts, glaucoma, macular swelling, or retinal detachment, which may cause permanent vision loss.
Treatment duration varies; some patients need medication only for months, while others require long-term therapy to prevent relapses and maintain eye health.
Steroids can cause increased eye pressure, cataracts, and systemic effects like weight gain or mood changes. Regular monitoring helps minimize risks.
No, it is not contagious. It usually results from immune system reactions or infections that are not spread by casual contact.
Yes, both eyes are commonly involved, although symptoms may be more severe in one eye.
Common complications include cataracts, glaucoma, macular edema, retinal detachment, and optic nerve damage, especially if inflammation is uncontrolled.
Increased floaters, worsening vision, eye pain, redness, light sensitivity, flashes, or vision loss require urgent evaluation.
Yes, children and teenagers can develop this condition, often associated with systemic diseases. Early diagnosis and treatment are important to protect vision development.
Active inflammation can interfere with reading, driving, screen use, and outdoor activities, though proper treatment usually restores function.
Regular eye exams, imaging tests, and sometimes blood tests help track disease activity and treatment effects.
While not a substitute for medical treatment, healthy diet, exercise, stress management, and avoiding smoking support overall eye health.
Surgery is reserved for cases where medications fail or complications develop, such as severe vitreous opacities or retinal detachment.
Biologic therapies targeting specific immune pathways may be used for cases resistant to conventional treatments, under specialist care.
Yes, it can recur even after successful therapy, making ongoing monitoring important.
Pregnancy may improve or worsen the condition. Treatment plans may need adjustment to ensure safety for mother and baby, with close specialist collaboration.
Many patients benefit from connecting with support organizations for information and emotional support through their journey.
Taking Care of Your Eyes
Managing intermediate uveitis successfully requires a partnership with your eye care team, adherence to treatment, protective measures, and healthy habits to maintain your vision and quality of life.